HAEE–zinc–albumin formulation — RU2709539C1
Sergey A. Kozin, Alexander O. Morozov, Vladimir P. Chuev, Andrey A. Buzov, Valentina S. Kazakova · 2019 · RU2709539C1 · patent family RU2709539C1
Published 2019-12-18.
Reported patent results
Reported findings
Approximately 2× the half-life and 5× the apparent brain distribution compared with unformulated HAEE.
Example 3 and Table 6 compare the formulation with unformulated HAEE after a single 0.05 mg/kg intraperitoneal dose (HAEE equivalent) in C57BL/6 mice. The example lists N=36.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Elimination half-life and brain distribution | Approximately 2× the half-life and 5× the apparent brain distribution compared with unformulated HAEE. |
These estimates apply to the albumin formulation in the mouse comparison. The preparation differs from the binary zinc complex and the PGP-extended peptide.
Source for these results ↗ · Reviewed 2026-11-12
Patent claims and provenance
Formulation. Claims a composition of HAEE, zinc ions and human serum albumin.
These estimates apply to the albumin formulation in the mouse comparison. The preparation differs from the binary zinc complex and the PGP-extended peptide.
- Publication
- RU2709539C1 ↗ · 2019-12-18
- Earliest priority / filing
- 2019-08-15 / 2019-08-15
- Original applicant / assignee
- VladMiVa experimental plant
- Indexed status
- Not shown; official status unverified · checked 2026-11-12
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
HAEE–zinc–albumin formulation
Inventors: Sergey A. Kozin; Alexander O. Morozov; Vladimir P. Chuev; Andrey A. Buzov; Valentina S. Kazakova.
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- These estimates apply to the albumin formulation in the mouse comparison. The preparation differs from the binary zinc complex and the PGP-extended peptide.
- These estimates apply to the albumin formulation in the mouse comparison. The preparation differs from the binary zinc complex and the PGP-extended peptide.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Available format: Original patent text and indexed metadata
Material reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related publications may cover the same research program or participants.
Source access
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Source reviewed 2026-11-12.
Source type: Patent publication
Citation and original source
Original source: Sergey A. Kozin, Alexander O. Morozov, Vladimir P. Chuev, Andrey A. Buzov, Valentina S. Kazakova. HAEE–zinc–albumin formulation — RU2709539C1 RU2709539C1 · patent family RU2709539C1 2019.
Molekul research summary: https://molekul.io/research/patent-ru2709539c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry